# EDGAR Filing Document

**Accession Number:** 0001581280
**File Stem:** 0000000000-26-001690
**Filing Date:** 2026-2
**Character Count:** 2976
**Document Hash:** b2cd15cad040e3fcc82eed49abde9a73
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001690.hdr.sgml**: 20260403

**ACCESSION NUMBER**: 0000000000-26-001690

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260219

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Twist Bioscience Corp
- **CENTRAL INDEX KEY:** 0001581280
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462058888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-38720

**BUSINESS ADDRESS:**
- **STREET 1:** 681 GATEWAY BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 800-719-0671

**MAIL ADDRESS:**
- **STREET 1:** 681 GATEWAY BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001581280-25-000025

## Text-Extract

```

                                                            February 19, 2026

Adam Laponis
Chief Financial Officer
Twist Bioscience Corporation
681 Gateway Blvd
South San Francisco, CA 94080

       Re: Twist Bioscience Corporation
           Form 10-K for Fiscal Year Ended September 30, 2025
           Form 10-Q for Quarterly Period Ended December 31, 2025
           File No. 001-38720
Dear Adam Laponis:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-Q for the Quarterly Period Ended December 31, 2025
Exhibits

1.     We note the certifications provided in Exhibits 31 and 32 refer to the
incorrect form and
       period. Please file a full amendment to your Form 10-Q with corrected
certifications that
       refer to the proper form and period. Refer to Item 601(b)(31) and
(b)(32) of Regulation
       S-K and Regulation S-K C&DI 246.14.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.
 February 19, 2026
Page 2

       Please contact Lynn Dicker at 202-551-3616 or Tara Harkins at
202-551-3639 with any
questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._